Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Busy ROR Gamma T Space Offers Small Molecule Promise In Autoimmune Disorders

Executive Summary

Amgen’s July 31 deal with Japan’s Teijin marks at least the six partnerships around RORγt inhibitor compounds since 2009, with one more such deal likely this year. Plus news from a busy deal-making week, including tie-ups for AstraZeneca and Fibrogen, Actelion and Ceptaris, and Bristol and Samsung.

Advertisement

Related Content

Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?
Cubist’s Time To Shine: Antibiotic Specialist Acquires Optimer, Trius
Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
AstraZeneca’s “Smart Risks” Include Sharing FibroGen’s Anemia Compound With Astellas
Actelion, Under Pressure To Diversify, Eyes Rare Disease Start-Up Ceptaris
Autoimmune RORγt Program May Portend Change Of Direction For Vitae

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055519

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel